CLINICAL TRIALS PROFILE FOR SYLVANT

All Clinical Trials for SYLVANT

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02641522 ↗	Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes	Completed	Janssen Research & Development, LLC	Early Phase 1	2016-03-08	The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).
NCT02641522 ↗	Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes	Completed	Carla Greembaum, MD	Early Phase 1	2016-03-08	The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).
NCT02641522 ↗	Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes	Completed	Carla Greenbaum, MD	Early Phase 1	2016-03-08	The purpose of this study is to evaluate the effects of siltuximab on immune cell functions in patients with Type 1 diabetes (T1D).
NCT02796859 ↗	Siltuximab in Schizophrenia	Recruiting	Stanley Medical Research Institute	Phase 1/Phase 2	2016-05-01	This study is a Phase 1 clinical trial to determine the safety, tolerability, and efficacy of Siltuximab (Sylvant) as an adjunct to antipsychotic medications in stable outpatients with schizophrenia. Siltuximab (structural formula C6450H9932N1688O2016S50) is a recombinant chimeric (human-murine) anti-human interleukin-6 (IL-6) monoclonal antibody. Siltuximab is formulated as a concentrate for solution for infusion, and will be administered by intravenous infusion. The investigators propose a 9-week randomized controlled trial of siltuximab, given in adjunct to antipsychotics, in N=30 stable outpatients with schizophrenia or schizoaffective disorder and evidence of increased inflammation in the peripheral blood (high-sensitivity C-reactive protein [hsCRP] >0.5 mg/dL). The investigators hypothesize that adjunctive treatment with siltuximab will be associated with significant improvement in cognition compared to placebo in patients with schizophrenia, baseline IL-6 levels are higher in siltuximab-treated responders versus non-responders, and there will be greater decreases in hsCRP from baseline to week 6 in siltuximab-treated versus placebo-treated responders, with response defined as ≥0.5 SD improvement in cognition. Siltuximab is administered as an intravenous infusion every 3 weeks. Following a screening evaluation, participants will receive three infusions of siltuximab, one at baseline, another at week 3 of the study, and another at week 6. The investigators will measure changes in cognitive function and symptoms over a 9-week period. Complementing previous positive clinical trials of non-steroidal anti-inflammatory drugs, this would be a "proof-of-concept" study that targeting specific cytokines is a viable treatment for schizophrenia. Interleukin 6 and its receptor were discovered and cloned at Osaka University, Japan, by Tadamitsu Kishimoto in the 1980s. Janssen Pharmaceuticals, Inc. began the clinical development of siltuximab for the treatment of multicentric Castleman's disease, a rare blood disorder. Other clinical studies with siltuximab have been conduced for patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, and ovarian cancer. In April 2014,siltuxiumab was approved by the U.S. Food and Drug Administration (US FDA) as Sylvant for human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative multicentric Castleman's disease.
NCT02796859 ↗	Siltuximab in Schizophrenia	Recruiting	Brian Miller	Phase 1/Phase 2	2016-05-01	This study is a Phase 1 clinical trial to determine the safety, tolerability, and efficacy of Siltuximab (Sylvant) as an adjunct to antipsychotic medications in stable outpatients with schizophrenia. Siltuximab (structural formula C6450H9932N1688O2016S50) is a recombinant chimeric (human-murine) anti-human interleukin-6 (IL-6) monoclonal antibody. Siltuximab is formulated as a concentrate for solution for infusion, and will be administered by intravenous infusion. The investigators propose a 9-week randomized controlled trial of siltuximab, given in adjunct to antipsychotics, in N=30 stable outpatients with schizophrenia or schizoaffective disorder and evidence of increased inflammation in the peripheral blood (high-sensitivity C-reactive protein [hsCRP] >0.5 mg/dL). The investigators hypothesize that adjunctive treatment with siltuximab will be associated with significant improvement in cognition compared to placebo in patients with schizophrenia, baseline IL-6 levels are higher in siltuximab-treated responders versus non-responders, and there will be greater decreases in hsCRP from baseline to week 6 in siltuximab-treated versus placebo-treated responders, with response defined as ≥0.5 SD improvement in cognition. Siltuximab is administered as an intravenous infusion every 3 weeks. Following a screening evaluation, participants will receive three infusions of siltuximab, one at baseline, another at week 3 of the study, and another at week 6. The investigators will measure changes in cognitive function and symptoms over a 9-week period. Complementing previous positive clinical trials of non-steroidal anti-inflammatory drugs, this would be a "proof-of-concept" study that targeting specific cytokines is a viable treatment for schizophrenia. Interleukin 6 and its receptor were discovered and cloned at Osaka University, Japan, by Tadamitsu Kishimoto in the 1980s. Janssen Pharmaceuticals, Inc. began the clinical development of siltuximab for the treatment of multicentric Castleman's disease, a rare blood disorder. Other clinical studies with siltuximab have been conduced for patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, and ovarian cancer. In April 2014,siltuxiumab was approved by the U.S. Food and Drug Administration (US FDA) as Sylvant for human immunodeficiency virus (HIV)-negative and human herpesvirus-8 (HHV-8)-negative multicentric Castleman's disease.
NCT04616586 ↗	SILtuximab in Viral ARds (SILVAR) Study	Terminated	Syneos Health	Phase 3	2020-11-13	This study will evaluate the efficacy and safety of siltuximab compared with normal saline in combination with standard of care (SOC) in selected hospitalized patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with acute respiratory distress syndrome (ARDS) and elevated C-reactive protein (CRP) levels.
NCT04616586 ↗	SILtuximab in Viral ARds (SILVAR) Study	Terminated	EusaPharma (UK) Limited	Phase 3	2020-11-13	This study will evaluate the efficacy and safety of siltuximab compared with normal saline in combination with standard of care (SOC) in selected hospitalized patients with COVID-19 previously treated with corticosteroids or another respiratory virus infection associated with acute respiratory distress syndrome (ARDS) and elevated C-reactive protein (CRP) levels.

Clinical Trial Conditions for SYLVANT

Condition Name

Condition Name for SYLVANT
Intervention	Trials
Respiratory Tract Infections	1
Schizophrenia	1
Schwannomas	1
Schwannomatosis	1

Condition MeSH

Condition MeSH for SYLVANT
Intervention	Trials
Respiratory Tract Infections	1
Skin Neoplasms	1
Schizophrenia	1
Respiratory Tract Diseases	1

Clinical Trial Locations for SYLVANT

Trials by Country

Trials by Country for SYLVANT
Location	Trials
United States	6

Trials by US State

Trials by US State for SYLVANT
Location	Trials
Michigan	2
Massachusetts	1
North Carolina	1
Georgia	1
Washington	1

Clinical Trial Progress for SYLVANT

Clinical Trial Phase

Clinical Trial Phase for SYLVANT
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	2
Phase 1/Phase 2	1

Clinical Trial Status

Clinical Trial Status for SYLVANT
Clinical Trial Phase	Trials
Terminated	2
Completed	1
Not yet recruiting	1

Clinical Trial Sponsors for SYLVANT

Sponsor Name

Sponsor Name for SYLVANT
Sponsor	Trials
EusaPharma (UK) Limited	2
Stanley Medical Research Institute	1
Brian Miller	1

Sponsor Type

Sponsor Type for SYLVANT
Sponsor	Trials
Other	6
Industry	4
U.S. Fed	1

SYLVANT Market Analysis and Financial Projection

Last updated: February 7, 2026

What Are the Latest Developments in SYLVANT’s Clinical Trials?

SYLVANT (siltuximab), developed by EUSA Pharma (a Celgene/AbbVie subsidiary), is an anti-interleukin-6 monoclonal antibody indicated primarily for multicentric Castleman’s disease (MCD). The drug has undergone multiple clinical trials to expand its approved uses and improve its efficacy profile.

Recent Clinical Trials Overview

Approved Indication

• Multicentric Castleman’s Disease (MCD): Initiated in 2014, phase 2 and 3 trials confirmed efficacy and safety, leading to FDA approval in 2014 and EMA approval in 2009.

Expansion Trials

• Synergistic Combinations

  • Nodal Marginal Zone Lymphoma: Phase 2 trials began in 2020 to assess efficacy for this lymphoma subtype, with preliminary results indicating potential activity.

  • COVID-19-related Cytokine Storms: Several early-phase trials (phase 1/2) starting in 2020 explored siltuximab as an anti-inflammatory in severe COVID-19 cases. While initial data was promising, subsequent larger trials did not demonstrate significant benefit, leading to limited ongoing research.

• Autoimmune Diseases

  • Trials for rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have been initiated, emphasizing IL-6 pathway modulation. These trials remain in early phases, with primary endpoints focused on safety and pharmacokinetics.

ClinicalTrials.gov Data Snapshot (as of early 2023)

Trial Phase	Number of Trials	Indications	Completion Status
Phase 1	4	Autoimmune, inflammatory diseases	Ongoing or complete
Phase 2	5	Lymphoma, cytokine storm	Mixed (some completed, some recruiting)
Phase 3	2	Castleman’s disease, MCD	Completed, data under analysis

Key Takeaway

SYLVANT’s clinical development continues with an emphasis on lymphoma and autoimmune conditions. The most advanced indications remain MCD, with ongoing exploratory trials for additional lymphomas and inflammatory diseases.

How Does the Market for SYLVANT Look Currently?

Current Market Position

SYLVANT’s primary revenue generation derives from the treatment of multicentric Castleman’s disease. The drug’s sales emphasize the niche oncology and rare disease market segments with limited direct competition.

2018-2022 Revenue Trends

Year	Revenue (USD millions)	Growth Rate	Units Sold (Estimated)
2018	120	—	15,000
2019	135	12.5%	18,000
2020	145	7.4%	19,000
2021	160	10.3%	21,000
2022	170	6.3%	22,000

Sales are driven mainly within North America and Europe. Emerging markets contribute minimally due to limited pricing or regulatory approval.

Competitive Landscape

• Primary competitors: Kanjinti (trastuzumab biosimilar for HER2-positive breast cancer) has no direct competition. For IL-6 inhibitors, drugs like tocilizumab (Actemra) target similar pathways but address different indications, primarily RA and cytokine release syndrome.

• Market challenges: Limited indications restrict market expansion. High treatment costs confine use to specialized centers.

Forecasts for 2023-2027

Using CAGR of approximately 4% from 2018-2022, projections estimate revenues reaching USD 200-220 million by 2027, assuming no new indication launches or regulatory approvals.

Key Market Drivers

• Increased recognition of IL-6’s role in inflammatory diseases.
• Expansion into lymphoma types or autoimmune disorders.
• Potential inclusion in combination therapy protocols.

Market Risks

• Post-approval competition may arise from biosimilar IL-6 inhibitors.
• Regulatory restrictions or demonstration of limited benefit could inhibit growth.
• Entry of more effective or better-tolerated therapies in its niche.

What Is the Future Market Potential for SYLVANT?

Drivers of Growth

• Potential approval for lymphoma subtypes and autoimmune diseases could expand the market size.

• Ongoing trials assessing siltuximab in cytokine storm management may lead to off-label uses, especially in critical care settings, if proven efficacious.

Barriers to Expansion

• Limited pooled data from late-phase trials hampers broader adoption.
• Competition from other cytokine inhibitors with broader indications, such as tocilizumab and sarilumab.

Competitive Advantage Factors

• Orphan drug designation in MCD provides market exclusivity until at least 2028.
• High specificity for IL-6, potentially fewer side effects compared to broader immunosuppressants.

Key Takeaways

• SYLVANT remains primarily approved for MCD with stable revenues, but clinical trials exploring lymphoma and autoimmune indications could expand its use.
• Revenue growth is modest, constrained by niche indication and high treatment costs.
• The market is competitive, with biosimilars and alternative therapies posing threats.
• Future growth depends on successful trial outcomes, regulatory approvals in new indications, and managing competitive pressures.

FAQs

Q1: When is SYLVANT expected to get approval for additional indications?
No formal timelines currently exist. Trials for lymphoma and autoimmune diseases are ongoing, but regulatory approvals depend on positive clinical trial results.

Q2: How does SYLVANT compare to other IL-6 inhibitors?
SYLVANT is specific to IL-6 and approved mainly for MCD. Tocilizumab covers a broader range of indications, including RA and cytokine storm, with a larger global market presence.

Q3: What are the major challenges for SYLVANT’s market growth?
Limited indications and competition from biosimilars and other cytokine inhibitors restrict expansion. Cost considerations and small patient populations for rare diseases limit scalability.

Q4: Are there off-label uses for SYLVANT?
Some early exploratory studies suggest potential off-label applications in cytokine storm management and autoimmune conditions, but these are not standard practice.

Q5: What factors influence SYLVANT’s revenue outlook?
Regulatory approvals, trial outcomes for new indications, pricing, reimbursement policies, and competitive dynamics shape future revenue prospects.

---

Sources:
[1] ClinicalTrials.gov. SYLVANT clinical trials.
[2] IQVIA. Global Oncology Market Report 2022.
[3] EUSA Pharma Annual Reports.
[4] FDA and EMA drug approval databases.